Prostagen Study - Investigation of polymorphisms in genes of the fatty acid metabolism in relation to the evolvement and further development of prostate cancer

Klinik für Tumorbiologie0 个研究点目标入组 158 人开始时间: 2010年2月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patient inclusion criteria:
•- Patients with histologically proven prostate cancer who are treated or advised in one of the centers involved in the study
•- Written informed consent
•Inclusion criteria for healthy subjects:
•- Subjects without prostate cancer or any other tumor, which are screened in one of the study centers and are 70 years or older.
•- Exclusion of prostate cancer according to one of the following criteria:
•* Men with a PSA level of maximum 10 ng/ml, who underwent a 12x punch biopsy with a negative result.
•* Men with benign prostatic hyperplasia (BPH), in whom a transurethral resection of the prostate (TUR-P) was conducted and the histology of the recovered material was negative (PSA maximum 10 ng /l).
•* PSA less than 4ng/l and no prostate cancer family history
•- Written informed consent

•- Patients / healthy subjects with a known allergy to seafood
•- Patients / healthy subjects who can not eat or are on a special diet
•- Patients / healthy subjects with malabsorption (i.e. after gastrointestinal surgery, inflammatory bowel disease)
•- Patients / healthy subjects with severe internal diseases, especially with impaired coagulation, liver or gall bladder disease, bile duct tumors, or pancreatitis
•- Patients / healthy subjects who are already taking omega-3 fatty acids supplementation or other dietary supplements and drugs that are likely to affect the results of the research
•- Patients / healths subjects with psychiatric or CNS disorders, who are not able to consent to participation in the study

发起方

Klinik für Tumorbiologie